2Myers ER, Barber MD, Gustilo-Ashby T, et al. Management of uterine leiomyomata: what do we really know? [ J ] Obstet Gyneeol, 2002,100:8-17
3Day Baird D, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women : ultrasound evidence [ J ]. Am J Obstet Gynecol,2003,188: 100-107
4Cook JD, Walker CL. Treatment strategies for uterine leiomyoma: the role of hormonal modulation [ J ]. Semin Reprod Med,2004,22 : 105-111
5Nisolle M, Gillerot S, Casanas-Roux F, et al. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy [ J ]. Hum Reprod, 1999,14:2844-2850
7Chia CC, Huang SC, Chen SS, et al. Uhrasonographic evaluation of the change in uterine fibroids induced by treatment with a GnRH analog [ J ]. Taiwan J Obstet Gynecol, 2006,45 : 124-128
8Di Lieto A, De Falco M, Pollio F, et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas [ J ]. J Soc Gynecol Investig,2005,12 : 123-128
9Di Lieto A, De Falco M, Mansueto G, et al. Preoperative administration of GnRH-a plus tibolone to premenopausal women with uterine fibroids:evaluation of the clinical response, the immunohistochemical expression of PDGF, bF- GF and VEGF and the vascular pattern [ J ]. Steroids, 2005,70 : 95-102
10Palomba S, Orio F Jr, Russo T, et al. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas [J]. Hum Reorod, 2004,19:1308-1314
